1. Home
  2. GGR vs RLYB Comparison

GGR vs RLYB Comparison

Compare GGR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

N/A

Current Price

$2.82

Market Cap

83.3M

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$15.62

Market Cap

89.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGR
RLYB
Founded
2011
2018
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
89.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
GGR
RLYB
Price
$2.82
$15.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.3K
★ 24.4K
Earning Date
11-11-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 5.64
Revenue
N/A
★ $858,000.00
Revenue This Year
$4.97
N/A
Revenue Next Year
$6.11
N/A
P/E Ratio
★ N/A
$2.80
Revenue Growth
N/A
★ 43.00
52 Week Low
$2.02
$0.56
52 Week High
$5.43
$32.54

Technical Indicators

Market Signals
Indicator
GGR
RLYB
Relative Strength Index (RSI) 42.57 40.96
Support Level $2.51 $7.93
Resistance Level $3.32 $16.89
Average True Range (ATR) 0.14 1.79
MACD -0.03 -0.00
Stochastic Oscillator 18.07 2.78

Price Performance

Historical Comparison
GGR
RLYB

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: